

Anabolic Lab™

Analytical Lab Testing for
Anabolic Steroid Harm Reduction

<https://anaboliclab.com>

Lab Report – March 27, 2018

ParaPharma
Testo C 250 (250 mg/mL)
Testosterone Cypionate



If you like the attached report, please visit [our website](https://anaboliclab.com) to find out how you can support independent and objective lab testing.

Test report

Number **C 67086**

Object of analysis: Parapharma Testo C 250

Customer: AnabolicLab.com

Samples: 1

Batch: PARA002, Exp. 08/2022

Receipt: 28.02.2018

Subject: Content, Identification


Method(s): HPLC

Ansatz-
datum 09.03.2018

Sample / Analysis:	Method	Status	Result	Specification	complies
<u>Testosterone Cypionate:</u>					
Identification	HPLC	N	complies	complies	yes
Content	HPLC	N	258.4 mg / ml	250 mg / ml	-
TAMC	SOP M 006	N	< 1 KBE/ml	-	-
TYMC	SOP M 006	N	< 1 KBE/ml	-	-

Method-status: G = GMP A = accredited V = generally validated P = validated on product N = not validated
 E = external lab

Remarks: The sample(s) mentioned above have been analysed as they have been sent to us by the client. We have not controlled external processes like manufacturing, labelling, sampling, shipping, storage. These results are for information only and do not compensate for correct quality control by the manufacturer/distributor. Generally, pharmaceutical products have to be produced and distributed under full GMP/GDP regime, including GMP-compliant analyses with validated methods. This report cannot be used for commercial reasons incl. product release and/or quality control. It is not allowed to use this analysis in the context of doping/sports/competitions or any other illegal action, neither by the athlete nor by the tutor/trainer or any other person.

Signatures: controlled & released: 

Staff: 

completed:

27.03.2018

The enclosed results refer exclusively to the object of examination described above. The measuring accuracy is available on request. Only handwritten signatures are valid.

Without written permission, it is not allowed to publish single parts of this report.

page 1 of 1